MEDLINE® (MEDlars onLINE)
Subject
Coverage

All areas in the broad field of biomedicine

File Type

Bibliography

Features

Thesauri:Chemical Name (/CN)
Controlled Term (/CT)
MeSH Tree Number (/MN)
The thesauri do not apply to terms in the OLDMEDLINE file segment.

Alerts (SDIs)

Every update (6 times/week), weekly or monthly (default is weekly)

CAS Registry
Number® IdentifiersPage Images

Keep & Share




SLART




Learning Database

Structures

RecordContent

•
•
•
•
•
•

File SizeMore than 35.9 million records (08/2023)

Coverage

1946-present

Updates

Six times each week, with an annual reload

Language

English

Database
Producer

U.S. National Library of Medicine (NLM)
8600 Rockville Pike
Bethesda, MD 20894 USA
Phone: 301-594-5983
Phone: 888-346-3656

Sources

•
•
•
•
•
•

Over 92% of MEDLINE's citations are references to journal articles
Approximately 68% of the citations contain abstracts
Most records for documents published before 1975 do not have abstracts
MEDLINE reference data is present in the file
CAS Registry Numbers are present in the file
About 86% of MEDLINE's citations represent publications in the English language

About 5,300 journals
Citations from Index Medicus
Index to Dental Literature
HealthSTAR database
International Nursing Index
OLDMEDLINE, data from NLM's Cumulated Index Medicus (CIM) (1960 through 1965)
and from Current List to Medical Literature (1949 through 1959)

August 2023

2
MEDLINE

User Aids••••

Clusters• ALLBIB• AUTHORS• BIOSCIENCE• CASRNS• CORPSOURCE• ENVIRONMENT• FORMULATIONS• HEALTH• MEDICINE• PHARMACOLOGY• PV• TOXICOLOGYSTN Database Clusters information (PDF)

August 2023

Medical Subject Headings - MeSH Browser: http://www.nlm.nih.gov/mesh/
List of Serials Indexed for Online Users: http://www.nlm.nih.gov/tsd/serials/lsiou.html
Online Helps (HELP DIRECTORY lists help messages available)
STNGUIDE

3
MEDLINE

Search and Display Field Codes
NLM represents that the databases provided hereunder were formulated with a reasonable standard of care. NLM makes norepresentations or warranties, expressed or implied, including but not limited to, any implied warranty of merchantability or
fitness for a particular purpose, with respect to such databases and specifically disclaims all such warranties andrepresentations. Some material in these databases is from copyrighted publications of the respective copyright claimants.
Users of the databases are referred to the publications data appearing in the bibliographic citations, as well as to the
copyright notices appearing in the original publication, all of which are hereby incorporated by reference.
The fields that allow left truncation are marked with an asterisk (*).
SearchCode

Search Field Name

Display
Codes

Search Examples

Basic Index * (contains single words fromthe title (TI), chemical name (CN), genename (GEN), controlled term (excluding
MeSH numbers) (CT), supplementaryterm (ST), named person (NA), othersource (OS), and abstract (AB) fields, aswell as CAS Registry Numbers and
GenBank Numbers)

None (or /BI)S INTERFERON GAMMA
S 50-02-2
S GENBANK D64071
S HEART (S) TEST#S ?FERON?
S EC3.1.3.13
S GAMMA (S) INTERFERONAB, CN, CT,
GEN, NA, OS,
RN, ST, TI

Abstract *

/AB

AB

Abstract Languages (other) (3)Accession Number

/ABLA
/AN

Accession Number of the Cited Referencein MEDLINE
AuthorAuthor Group
Author Identifier
Chemical Name (1)/RAN.MED

S ?ASSAY?/AB
S RADIOACTIVE TRACER/AB
S (LEUKEMIA (S) GLEEVEC)/ABS SPANISH/ABLAS 1965153674/AN
S 1998010009/AN
S 1967176588/RAN.MED

AU
AUTH
AUID
CN, RN

Chemical Name Segment * (1)Cited Reference First Author Name
Cited Reference First Author Name,
Extended (12)Cited Reference Count (6)Cited Reference Issue Number
Cited Reference Page Number
Cited Reference Publication Year
Cited Reference Source Publication
Cited Reference Volume Number

/CNS
/RAU
/RAU.EXS ADAMSON G?/AU
S BROOKS A?/AUTH
S 0000-0003-3785-6868/AUID
S NIFEDIPINE/CN
S EC 1.11.1.6/CN
S ?FLUOR?/CNSS DEANDRADE A L/RAU
S DEANDRADE A L?/RAU.EX/RE.CNT
/RIS
/RPG
/RPY
/RSO
/RVL

S 15-20/RE.CNT
S 12/RISS 32/RPG
S 2007/RPY
S JAMA/RSO
S 22/RVL

RE.CNT
RE
RE
RE
RE
RE

Cited Reference Source Publication Name
Cited References
Cited References, Extended (12)Citing Reference Accession Numbers(limit 50)
Citing Reference Count (6)S MED ARTS SCI/RWKS DELPHIA J M?/RES WALKER B 1992?/RE.EX
S 2014206241/OS.G

Clinical Trial Numbers

/RWK
/RE
/RE.EX/OS.G (or/OS.CITING.AN)/OSC.G(/CITING.CNT)
/NCT

RE
RE
RE
OS.G,
OS.CITING.AN
OSC.G,CITING.CNT
NCT

Collaborators
Comment
Controlled Term (2) (includes main terms)

/AUCL
/CM
/CT

Corporate Source (3,4) (includes Collective
Name)
Country of Publication (ISO code and text)

/CS

/AU
/AUTH
/AUID
/CN

/CY

S 13/OSC.GS ISRCTN03464021/NCT
S NCT00005487/NCT
S BEGAY JACK/AUCLS TOXICOL?/CM
S OVARIAN FOLLICLE/CT
S (HYPERTENSION(L)BL)/CT
S (C14.907.489. (L) TH)/CTS *BRAIN/CT
S (KYUSHU(W)CANCER(W)CENTER)/CSS ROSIGLITAZONE STUDY GROUP/CS
S L1 AND UNITED STATES/CY
S JP/CY

ABLA
AN
RE

CN, RN
RE
RE

AUCL
CM
CT

CS
CY
August 2023

4
MEDLINE

Search and Display Field Codes (cont'd)
SearchCode

Search Field Name
Digital Object Identifier
Document Number (contains
MEDLINE DN and the PubMed ID
number)Document Type (code and text) (5)Electronic Publication Date (6)Electronic Publication Year (6)Email Address (3)Entry Date (6)Entry Month (6)Field Availability (7)File Segment (8)/FTDOI (or /DOI)/DN/DT(or /TC)
/EPD
/EPY
/EML
/ED
/EM
/FA
/FS

Display
Codes

Search Examples
S 10.1101?/FTDOIS 9875853/DN
S 6000001/DN
S 11300629/DN
S MULTICENTER STUDY/DT
S BIO/TC
S 21 DEC 2012
S 2013/EPY
S B.A.BRIDGES@SUSSEX.AC.UK/EML
S ED>20020500
S 199106/EM
S L2 AND AB/FA
S L8 AND PRIORITY JOURNALS/FS
S B/FSS DIABETES AND OLD/FSS IN-PROCESS/FSS CLINICAL TRIALS.GOV/FSS C-JUN/GEN
S R01 AG037506/GN
S NASA/GOS DALLAS EVE/AUGR
S 8756-8160/ISN

DOI, FTDOI
DNDT
EPD, SO
EPY, SO
CS, EMLED
EM
Not displayed
FS

Gene Name (3,9)
Grant Number (3)Grant Organization (3)Group Authors
International Standard (Document)
Number (contains CODEN, if
available, and ISSN)
Journal Title (contains full andabbreviated journal titles)

/GEN
/GN
/GO
/AUGR
/ISN

/JT

S BIOCHEM PHARMACOL/JTS BIOCHEMICAL PHARMACOLOGY/JT

JT, SO

Journal Title Code (3)

/JTC
/LA

SO
LA

MEDLINE Cited References Count (6)Named Person (10)Number of Report (3)/REM.CNT/NA/NR

Other Sources (3,11)/OS

Publication Date (6)Publication Year (6)Source (contains full and abbreviatedjournal titles, ISSN, CODEN, journal
title code, number of report, spaceflight mission, investigator, andaffiliation data, call number,publication year, volume, issue, andpagination)
Title *
Unique Ingredient Identifier
Update Date (6)Update Date Indexing Added (6)Date Last Citing Reference Entered
STN (6)

/PD
/PY
/SO

S 0101032/JTC
S GERMAN/LAS RU/LAS 5-10/REM.CNTS PRIMROSE J/NA
S NASA-00001303/NR
S NASA/NR
S CLML5936/OS
S GENBANK L02896/OS
S 2005 OCT 4/PD
S L1 AND 1990-1992/PY
S 0006-2952/SO
S BIOCHEM PHARMACOL/SO
S 7802429/SO
S NASA00001303/SO
S FLIGHT EXPERIMENT/SOS TOOTH MOVEMENT/TIS 8SSC91326P/UNIIS UP>20030200 AND L4
S UPI>20140707
S 20140107/UPOS.G
S CITING.UP>20140107

TI
UNII
ED, UP
ED, UPI
UPOS.G, UPOG,

(1)

/TI
/UNII
/UP
/UPI
/UPOS.G (or/UPOG,/CITING.UP)

GEN
GN
GO
AUGR
ISN, SO

REM.CNTNA
NR, SOOS
PD, SOPY, SOSO

CITING.UP

CAS Registry Numbers and Enzyme Codes can also be searched in this field. A /CN Thesaurus is available online. Starting on
November 19, 2000, a new relationship, +XUSE, has been defined for EXPAND and SEARCH in the /CN field. XUSE includes both
USE and UF terms. When you EXPAND in the /CN field, a message is displayed if additional terms are available by using the +XUSE
relationship. If there are additional USE or UF terms available for a search in the /CN field, they are automatically included in the
search.
(2) MeSH Tree Numbers are also searched in this field. (L) proximity is available with Qualifiers. Postings for MeSH Headings do notinclude narrower terms, while MeSH Tree Numbers do include all narrower levels. /CT and /MN Thesauri are available online. Startingon November 19, 2000, a new relationship, +XUSE, has been defined for EXPAND and SEARCH in the /CT field. XUSE includes both
August 2023

5
MEDLINE
USE and UF terms. When you EXPAND in the /CT field, a message is displayed if additional terms are available by using the +XUSE
relationship. If there are additional USE or UF terms available for a search in the /CT field, they are automatically included in the
search. To limit retrieval to major MeSH concepts place an asterisk before the MeSH controlled term of interest, e.g., S *BRAIN/CT. In
addition, when the Controlled Terms are displayed, the major MESH concepts of the article also have a preceding asterisk (*).
(3) This field is not available for records in the OLDMEDLINE file segment.
(4) Search with implied (S) proximity is available in this field.
(5) Both STN standard document types and original NLM publication types (displayed in parenthesis) are searchable separately as boundphrases.
(6) Numeric search field that may be searched using numeric operators or ranges.
(7) The presence of AB, CN, CS, EML, NA, OS, RN, ST fields can be searched in the /FA field; as well as the sections of the structured
abstract: Background, Conclusions, Methods, Objective, and Results.
(8) Enter HELP FS at an arrow prompt for definitions of the FS codes.
(9) Data indexed in this field only until 1996.
(10) Subject of biographical or related article.
(11) Enter HELP OS for information on the content of this field.
(12) When author’s name entered with multiple initials, automatically also searches the author’s name with a single initial.

Limiting Search Codes
Only an answer set created in MEDLINE may be limited. L-number answer sets created by a search in the /ED
or /UP field may also be limited. See HELP LLIMIT for further information.
Search Field Name
Animal Subject (1)English-Language Records
Female Subject (1)Human Subject (1)Major Descriptor (1)Male Subject (1)SearchCode/ANIMAL/ENG/FEMALE/HUMAN/MAJ/MALE

Search Examples
S L4/ANIMAL
S L1/MAJ,ENG (2,3)
S L3/FEMALE
S L1/HUMAN
S L1/MAJ
S L2/MALE(1) Not available in OLDMEDLINE file segment.
(2) Field codes may be abbreviated to the first three letters.
(3) Answer sets may be limited to more than one area.

Chemical Name (/CN) Thesaurus
All Relationship Codes can be used with both the SEARCH and EXPAND command in the Chemical Name(/CN) thesaurus. The /CN thesaurus does not apply to the OLDMEDLINE file segment.
Code
ALL

AUTO (1)
HM
NOTE
PFT
RN

RR
XUSE

Content
All associated terms(SELF, CN, RN, EC, UF, USE, RR, HM, PA, INDX, NOTE,
PNTE, RE)
Automatic Relationship Code
(SELF, USE)
Heading Mapped to(SELF, CN, RN, EC, RR, HM)
Notes associated with the term
(SELF, CN, RN, EC, RR, INDX, PA, NOTE, PNTE, RE)
Preferred and Forbidden Terms(SELF, CN, RN, EC, RR, UF, USE)
CAS Registry Number associated with the name or nameassociated with a CAS Registry Number(SELF, CN, RN, EC)
Associated CAS Registry Numbers and UNII Codes(SELF, CN, RN, EC, RR)
USE and UF terms from the current MeSH

ExamplesE CHAETOGLOBOSINS+ALL/CN
E 86414-29-1+ALL/CN
E BROMOACETIC ACID+AUTO/CNE CADMIUM ACETATE+HM/CN
E SERICYSTATIN+NOTE/CNE EC 2.4.1.119+NOTE/CNE COMBRETASTATIN+PFT/CNS ARGINYLPROLINE+RN/CN
E 2418-69-1+RN/CN
E FLUVALINATE+RR/CNE BKJ8M8G5HI+RR/CN
E 6-CHRYSENYLAMINE+XUSE/CN
S 6-CHRYSENAMINE+XUSE/CN(1) AUTOMATIC relationship is SET OFF. In case of SET REL ON, the result of EXPAND without any relationship code is the same as
described for AUTO.

August 2023

6
MEDLINE

Field Descriptors for the /CN Thesaurus
Code
-->
CN
EC
HM
INDX
NOTE
PA
PNTE
RE
RN
RR
UF
USE

August 2023

Description
Self
Chemical Name and Enzyme Name
Enzyme Commission Numbers
Heading Mapped To
Indexer Note
Scope Note
Pharmacological Action
Previous Indexing Note
Reference
CAS Registry Number
Related Registry Numbers and UNII Codes
Used ForUse7
MEDLINE

Controlled Term (/CT) Thesaurus
All Relationship Codes can be used with both the SEARCH and EXPAND command in the Controlled Term(/CT) thesaurus.
The /CT thesaurus contains the current Controlled Terms. MeSH Tree Numbers are searchable terms in the/CT thesaurus.
The /CT and /MN Thesauri have the same EXPAND abilities except when expanding MeSH Tree Numbers. The/CT Thesaurus will expand the same Tree Number hierarchy, while the /MN Thesaurus will expand the MeSH
terms corresponding to the various MeSH Tree Numbers.
The /CT thesaurus does not apply to the OLDMEDLINE file segment.
Code
ALL

AUTO (1)

BT
HIE
KT
MN
NOTE

NT
PFT
QLF

QPFT
RT
STD
UF
USE
XUSE

Content
All associated terms(BT, SELF, MN, DC, NOTE, INDX, ENTC, AQ, PNTE,
HNTE, MHTH, BXTH, PA, UF, USE, QUSE, NT, QLF,
QA, QCAT, QNOTE, QINDX, QHNTE, QONTE, QUF,
RT)
Automatic Relationship Code (Preferred Terms andQualifiers)(SELF, USE, QUSE)Broader Terms(BT, SELF, MN)
Hierarchy (Broader and Narrower Terms)(BT, SELF, MN, NT)
Keyword Terms(SELF, KT)
Tree Number and descriptor class(SELF, MN, DC)
Notes associated with the term
(SELF, MN, NOTE, INDX, ENTC, AQ, PNTE, HNTE,
ONTE, MHTH, BXTH, PA)
Narrower Terms(SELF, MN, NT)
Preferred and Forbidden Terms(SELF, MN, ENTC, AQ, UF, USE)
Qualifier and associated terms(SELF, AQ, QUSE, QLF, QA, QCAT, QNOTE, QINDX,QHNTE, QONOTE, QUF)
Qualifier Preferred(SELF, QUSE, QLF, QUF)
Related Terms(SELF, MN, RT)
Standard (Broader, Narrower, and Related Terms)(BT, SELF, MN, NT, RT)
Used For (Forbidden Terms)(SELF, MN, UF)
Use (Preferred Terms)(SELF, MN, USE)
USE and UF terms from the current MeSH

ExamplesE PEPTIC ULCER+ALL/CT
E C6.405.608+ALL/CT

E NASAL SINUSES+AUTO/CT
E ADV EFF+AUTO/CT
E PREGNANCY TESTS+BT/CT
E RECEPTORS, DRUG+HIE/CTS SHOCK+KT/CT
E PROSTHESIS FAILURE+MN/CT
S NUTRITIONAL STATUS+MN/CT
E PEPTIC ULCER+NOTE/CTS NEURONS+NT/CT
E FIBRIN TISSUE ADHESIVE+PFT/CTS ADVERSE EFFECTS+QLF/CT

E PSYCHOLOGY+QPFT/CT
E NEURONS+RT/CT
S SPINAL CORD+STD/CT
E PNEUMONIA+STD/CT
E F1.145.775.+UF/CT
E SEX BEHAVIOR+UF/CT
E GRAAFIAN FOLLICLE+USE/CT
E RADICULITIS+XUSE/CT(1) AUTOMATIC relationship is SET OFF. In case of SET REL ON, the result of EXPAND without any relationship code is the same as
described for AUTO.

August 2023

8
MEDLINE

Field Descriptors for the /CT Thesaurus
Code
-->
AQ
BT
BXTH
DC
ENTC
HNTE
INDX
KT
MH
MHTH
MN
NOTE
NT
ONTE
PA
PNTE
QA
QCAT
QHNTE
QINDX
QLF
QNOTE
QONTE
QUF
QUSE
RT
UF
USE

August 2023

Description
Self
Allowable Qualifier
Broader Term
Backwards Cross Reference Thesaurus
Descriptor Class
Entry Combination
History Note
Indexer Note
Keyword Terms
MeSH Heading
MH Thesaurus
MeSH Tree Number
Scope Note, Consider Also Terms
Narrower Term
Online Note
Pharmacological Action
Previous Indexing Note
Qualifier Abbreviation
Allowable Categories
Qualifier History Note
Qualifier Indexer Note
MeSH Qualifier (subheading)
Qualifier Scope Note
Qualifier Online Note
Qualifier Use For
Qualifier Use
Related Term
Used ForUse9
MEDLINE

MeSH Tree Number (/MN) Thesaurus
In the MeSH Tree Number (/MN) Thesaurus, all Relationship Codes can be used only with the EXPAND
command.
The /MN Thesaurus does not have any postings. When searching, it is necessary to edit the field code to /CT.
The /CT and /MN Thesauri have the same EXPAND abilities except when expanding MeSH Tree Numbers. The/CT Thesaurus will expand the same Tree Number hierarchy, while the /MN Thesaurus will expand the MeSH
terms corresponding to the various MeSH Tree Numbers.
The /MN thesaurus does not apply to the OLDMEDLINE file segment.
Code
ALL

AUTO (1)
BT
HIE
KT
MN
NOTE

NT
PFT
QLF

QPFT
RT
STD
UF
USE
XUSE

Content
All associated terms(BT, SELF, MN, MH, EC, DC, NOTE, INDX, ENTC, AQ,
PNTE, HNTE, ONTE, MHTH, BXTH, PA, UF, USE, QUSE,NT, QLF, QA, QCAT, QNOTE, QINDX, QHNTE, QONTE,
QUF, RT)
Automatic Relationship Code (Preferred Terms and Qualifiers)(SELF, USE, QUSE)Broader Terms(BT, SELF, MN, MH)
Hierarchy (Broader and Narrower Terms)(BT, SELF, MN, MH, NT)
Keyword Terms(SELF, KT)
Tree Number and descriptor class(SELF, MN, MH, DC)
Notes associated with the term
(SELF, MN, MH, NOTE, INDX, ENTC, AQ, PNTE, HNTE,
ONTE, MHTH, BXTH, PA)
Narrower Terms(SELF, MN, MH, NT)
Preferred and Forbidden Terms(SELF, MN, MH, ENTC, AQ, UF, USE)
Qualifier and associated terms(SELF, AQ, QUSE, QLF, QA, QCAT, QNOTE, QINDX,QHNTE, QONTE, QUF)
Qualifier Preferred(SELF, QUSE, QLF, QUF)
Related Terms(SELF, MN, MH, RT)
Standard (Broader, Narrower, and Related Terms)(BT, SELF, MN, MH, NT, RT)
Used For (Forbidden Terms)(SELF, MN, MH, UF)
Use (Preferred Terms)(SELF, MN, MH, USE)
USE and UF terms from the current MeSH

ExamplesE GRANULOMA+ALL/MN
E C23.550.382+ALL/MN

E PANCREATIC CHOLERA+AUTO/MN
E ILLUSIONS+BT/MN
E CHLAMYDIA+HIE/MN
E B3.440.190.190.190.+HIE/MN
E DIET+KT/MN
E ABSCESS+MN/MN
E SPINAL NERVES+NOTE/MN
E A8.800.350.380+NOTE/MN
E TOOTH+NT/MN
E HUMAN ADENOVIRUSES+PFT/MN
E B4.909.777.731.589.520+PFT/MN
E AE+QLF/MN

E METABOLISM+QPFT/MN
E TOMOGRAPHY, EMISSIONCOMPUTED+RT/MN
E ALCOHOLISM+STD/MN
E C21.739.100.250.+STD/MN
E IODIDE PEROXIDASE+UF/MN
E OPHTHALMIA+USE/MN
E ARSENIC POISONING+XUSE/MN(1) AUTOMATIC relationship is SET OFF. In case of SET REL ON, the result of EXPAND without any relationship code is the same as
described for AUTO.

August 2023

10
MEDLINE

Field Descriptors for the /MN Thesaurus
Code
-->
AQ
BT
BXTH
DC
ENTC
HNTE
INDX
KT
MH
MHTH
MN
NOTE
NT
ONTE
PA
PNTE
QA
QCAT
QHNTE
QINDX
QLF
QNOTE
QONTE
QUF
QUSE
RT
UF
USE

August 2023

Description
Self
Allowable Qualifier
Broader Term
Backwards Cross Reference Thesaurus
Descriptor Class
Entry Combination
History Note
Indexer Note
Keyword Terms
MeSH Heading
MH Thesaurus
MeSH Tree Number
Scope Note, Consider Also Terms
Narrower Term
Online Note
Pharmacological Action
Previous Indexing Note
Qualifier Abbreviation
Allowable Categories
Qualifier History Note
Qualifier Indexer Note
MeSH Qualifier (subheading)
Qualifier Scope Note
Qualifier Online Note
Qualifier Use For
Qualifier Use
Related Term
Used ForUse11
MEDLINEDISPLAY and PRINT Formats
Any combination of formats can be used to display or print answers. Multiple codes must be separated by spaces orcommas, e.g., D L1 1-5 TI AU. The fields are displayed in the order requested.
Hit-term highlighting is available in all fields except CM, ED, and PY. Highlighting must be ON to use the HIT, HITIND,
KWIC, and OCC formats.
FormatAB
ABLA
AN (1)
AU
AUCL
AUGR
AUID
AUPB (2,4)
AUTH
CM (1)
CN (1)CS (1)CT (1)CY (1)
DN (1)
DOI (FTDOI)DT (1)ED (1)EM (1)EML (1,2)
EPD (1,2)
EPY (1,2)
FS (1)GEN (1)GNGO
ISN (1,2)
ISSUE (2)
JT (1,2)
JTA (1,2)
JTF (1,2)
LA (1)
NA (1)NCT
NR (1,2)
OS (1)
OS.G (OS.CITING.AN)
OS.GMAX
OSC.G (CITING.CNT)
PD (1,2)
PGNO (2)PY (1,2)
RE
RE.CNT (REC)REM.CNTRN (1)SO
ST (1)
TC (1,2)
TI (1)UNIIUP
UPI
UPOS.G (CITING.UP)
VL (2)

Content
Abstract
Abstract Language (other)
Accession Number
AuthorCollaborators
Group Authors
Author Identifier
Authors in Publication Order
Author Group
Comment
Chemical Name (enzyme code and name)
Corporate Source
Controlled Term (MeSH terms, qualifiers)
Country of Publication
Document Number and PubMed ID
Digital Object Identifier
Document Type
Entry Dates
Entry MonthE-mail Address
Electronic Publication Date
Electronic Publication Year
File Segment
Gene Name
Grant Number
Grant Organization
International Standard (Document) Number
Issue
Journal Title (includes JTA and JTF)
Journal Title, Abbreviated
Journal Title, Full
Language
Named Person (subject of biography or related article)
Clinical Trial Numbers
Number of Report
Other Source
Citing Reference Accession Numbers (up to 50 accession numbers)
Citing Reference Accession Numbers (up to 1020 accession numbers)
Citing Reference Count
Publication Date
Page Number
Publication Year
Cited References in MEDLINE
Cited References CountMEDLINE Cited References CountCAS Registry Number (Registry Number and chemical name)SourceSupplementary Term
Treatment Code
Title
Unique Ingredient Identifier
Update Date
Update Date Indexing Added
Date Last Citing Reference Entered STN
VolumeExamplesD 1-5 AN, AB
D ABLA
D 1-5 AND AU TI 2
D AUCLD AUGRD AUID
D AUPBD AUTH
D AN CM TI 1-5
D CN, RN 8-10
D CS, AU 10-20
D AN CT 1-2
D CY TI
D DN
D DOI, D FTDOID DT TI
D ED
D TI SO EM
D EML
D EPD
D EPY
D FS TI 1-2
D GEN TI 1-2
D GN
D GO
D 2 6 ISND ISSUE
D 1-3 JT
D JTA
D JTF
D LA TI
D AN TI NA
D NCT
D NR
D TI SO OS
D OS.GD OS.GMAX
D OSC.GD PY SOD PGNO
D PY
D RE
D RE.CNT
D REM.CNT
D CT RN
D SO TI FS
D ST
D TC
D TI 1-10
D UNII
D UP, D ED
D UPI, D ED
D UPOS.G
D VL
August 2023

12
MEDLINE

Display and Print Formats (cont'd)Format
ABS
ALL

AU.CS
AUTH
BIB
CBIB
DALL
IABS
IALL
IBIB
IND (1)OSG
OSG.MAX
RAN.MEDLINE (n)RETAB (RETABLE)
SCAN (3)
TRIAL (FREE,
SAM) (1)HIT
HITIND (1)KWIC
OCC (1)

Content

ExamplesAB, ABLA
AN, DN, TI, AU.CS, SO, DOI, CM, CY, DT, LA, FS, NCT, OS, EM, ED, AB,
ABLA, ST, CT, RN, CN, UNII, GO, GN, NA, GEN, OSC.G, UPOS.G,
OS.G, RE.CNT, REM.CNT, RE
AU, AUID, CS (AU,AUID, CS repeat as needed), AUGR, AUID, CS(AUGR, AUID, CS repeat as needed), AUCL
AU, AUCL, AUGRAN, DN, TI, AU.CS, SO, DOI, CY, DT, LA, FS, NCT, OS, EM, ED, UP, GO,
GN, OSC.G, UPOS.G, OS.G, RE.CNT, REM.CNT (BIB is the default)
Compressed bibliographic information
ALL, delimited for post-processing
ABS, with a text label
ALL, indented with text labels
BIB, indented with text labels
CT, ST, RN, CN, UNII, NA, GEN
OSC.G, UPOS.G, OS.G (up to 50 accession numbers)
OSC.G, UPOS.G, OS.G (up to 1020 accession numbers)
Cited Reference(s) display feature (n=cited reference number(s)MEDLINE Cited References Table (RAU, RPY, RVL, RPG, RWK)
TI, ST, CT, RN, CN, NA, GEN (random display without answer numbers)
TI, ST, CT, RN, CN, NA, GEN

D ABS 1-3
D 1-3 ALL

Fields containing hit terms
IND
Hit term with 20 words on either side (KeyWord-In-Context)
Fields that contain hit terms and number of times they occur

D HIT 5-10
D HITINDD KWIC 5-10
D OCC L3 1-2

D AU.CSD AUTHD 8 BIB
D 2 CBIBD DALL
D IAB
D IALLD IBIBD BIB, IND
D OSG
D OSG.MAXD RAN.MEDLINE (n)D RETABD SCAN
D TRI(1) No online display fee for this format.
(2) Custom display only.
(3) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.
(4) If 100 or more authors are provided, only the first 99 are presented followed by et al.

Displaying MEDLINE documents for cited references
Enter the following in the DISPLAY command: L-number for the answer set; answer number (only one may be
specified); RAN.MEDLINE(x-y) where (x-y) is the cited reference number, numbers, or range of numbers; andthe display format for the document to display, e.g., BIB ABS. For example, to display MEDLINE records for thecited references 1 and 2 from answer 2 in the answer set L5, enter the following:=> D L5 2 RAN.MEDLINE(1-2) BIB ABS

August 2023

13
MEDLINE

SELECT, ANALYZE, and SORT Fields
The SELECT command is used to create E-numbers containing terms taken from the specified field in ananswer set.
The ANALYZE command is used to create an L-number containing terms taken from the specified field in ananswer set.
The SORT command is used to rearrange the search results in either alphabetic or numeric order of thespecified field(s).
Field Name

Field Code

Abstract
Abstract Language (other)
Accession Number
Accession Number of the Cited Reference in MEDLINE
AuthorAuthor Group
Author Identifier
Authors in Publication Order
CAS Registry Number
Chemical Name

AB
ABLA
AN
RAN.MED
AU
AUTH
AUID
AUPB
RN
CN
NAME
CHEM
CIT
RAU
RPY
RWK
RE
RE.CNT (REC)OS.G(OS.CITING.AN)
OSC.G (CITING.CNT)
NCT
AUCL
CM
CS
CT
CY
DN
DT
EPD
EPY
EML
EM
FS
GENBANK (GBN)
GEN
GN
GO
AUGR
HITRE
ISN
ISSN
JT
JTA
JTF
JTC
LA
REM.CNTNA
NR

Chemical Name and CAS Registry Number
Citation
Cited Reference First Author
Cited Reference Publication Year
Cited Reference Publication Name
Cited References
Cited Reference Count
Citing Reference Accession Numbers
Citing Reference Count
Clinical Trial Numbers
Collaborators
Comment
Corporate Source
Controlled Term
Country of Publication
Document Number
Document TypeElectronic Publication Date
Electronic Publication Year
Email Address
Entry Month
File Segment
GenBank Number
Gene Name
Grant Number
Grant Organization
Group Authors
Hit Cited Reference
International Standard (Document) Number (ISSN)
International Standard Serial Number
Journal Title
Journal Title, Abbreviated
Journal Title, Full
Journal Title Code
Language
MEDLINE Cited References Count
Named Person
Number of Report

ANALYZE/
SELECT (1)

SORT

Y
Y
Y
Y
Y
Y
Y
Y (12)
Y (2,3,4)
Y (4)Y (2,4)
Y (2,4)Y (4,5)
Y
Y
Y
Y
Y
Y

N
N
N
N
Y
Y
Y
N
N
N
N
N
N
N
N
N
N
Y
Y

Y
Y
Y
Y (10)
Y
Y
Y
Y (6)
Y
Y
Y
Y
Y
Y
Y (2,11)
Y
Y
Y
Y
N
Y (7)
N
Y
Y (8)
Y (8)
Y
Y
Y
Y
Y

Y
Y
Y
N
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y

August 2023

14
MEDLINE

SELECT, ANALYZE, and SORT Fields (cont'd)
Field Name
Occurrence Count of Hit Terms
Other Source
Publication Date
Publication Year
SourceSupplementary Term
Title
Treatment Code
Unique Ingredient Identifier
Date Last Citing Reference Entered STN

Field Code
OCC
OS
PD
PY
SO
ST
TI
TC
UNII
UPOS.G (UPOG,
CITING.UP)

ANALYZE/
SELECT (1)

SORT

N
Y
Y
Y (4)
Y (9)
Y (2)
Y (default)
Y
Y
Y

Y
Y
Y
Y
N
N
Y
Y
N
Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT TI.
(2) Appends /BI to the terms created by SELECT.
(3) Only extracts CAS Registry Numbers.
(4) SELECT HIT and ANALYZE HIT are not valid with this field.
(5) Extracts first author, publication year, volume, and first page with a truncation symbol appended and with /RE appended to the terms
created by SELECT. This field can be used for cross-file searching in SCISEARCH and CAplusSM.
(6) Selects or analyzes MEDLINE's Document Number and the PubMed ID.
(7) Selects or analyzes the ISSN and CODEN.
(8) Appends /JT to the terms created by SELECT.
(9) Selects or analyzes the ISSN, CODEN, and journal code with /SO appended to the terms created by SELECT.
(10) Selects or analyzes the PMID values with /DN appended.
(11) SELECT GENBANK selects GenBank numbers from the OS field.
(12) Appends /AU to the terms created by SELECT.

Sample Records
DISPLAY IALLACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

2015308911
MEDLINE (IN-PROCESS)
Full-text
PubMed ID: 25423041
Impact of Xpert MTB/RIF for TB diagnosis in a primary careclinic with high TB and HIV prevalence in South Africa: apragmatic randomised trial.
AUTHORS IN PUB ORD: Cox Helen S; Mbhele Slindile; Mohess Neisha; Whitelaw
Andrew; Muller Odelia; Zemanay Widaad; Little Francesca;
Azevedo Virginia; Simpson John; Boehme Catharina C; Nicol
Mark PAUTHOR:
Cox Helen S
CORPORATE SOURCE:
Division of Medical Microbiology and Institute for
Infectious Diseases and Molecular Medicine, University ofCape Town, Cape Town, South Africa, Medecins Sans
Frontieres, Khayelitsha, South Africa.
AUTHOR:
Mbhele Slindile; Mohess Neisha; Zemanay Widaad
CORPORATE SOURCE:
Division of Medical Microbiology, University of Cape Town,
Cape Town, South Africa.
AUTHOR:Whitelaw Andrew
CORPORATE SOURCE:
Division of Medical Microbiology, University of Cape Town,
Cape Town, South Africa, National Health Laboratory
Service, Johannesburg, South Africa.
AUTHOR:
Muller Odelia
CORPORATE SOURCE:
Medecins Sans Frontieres, Khayelitsha, South Africa.
AUTHOR:
Little Francesca
CORPORATE SOURCE:
Department of Statistical Science, University of Cape Town,
Cape Town, South Africa.
AUTHOR:
Azevedo Virginia
CORPORATE SOURCE:
Khayelitsha Health, City of Cape Town, Cape Town, South
Africa.
AUTHOR:
Simpson JohnCORPORATE SOURCE:
National Health Laboratory Service, Johannesburg, South
Africa.
AUTHOR:
Boehme Catharina C
August 2023

15
MEDLINECORPORATE SOURCE:

Foundation for Innovative New Diagnostics, Geneva,
Switzerland.
AUTHOR:
Nicol Mark P
CORPORATE SOURCE:
Division of Medical Microbiology and Institute for
Infectious Diseases and Molecular Medicine, University ofCape Town, Cape Town, South Africa.
SOURCE:
PLoS medicine, (2014 Nov) Vol. 11, No. 11, pp. e1001760.
Electronic Publication Date: 25 Nov 2014
Journal code: 101231360. E-ISSN: 1549-1676. L-ISSN:
1549-1277.
Report No.: NLM-PMC4244039.
DIGITAL OBJECT ID: http://dx.doi.org/10.1371/journal.pmed.1001760
PUB. COUNTRY:
United States
DOCUMENT TYPE:
Journal; Article; (JOURNAL ARTICLE)(RESEARCH SUPPORT, NON-U.S. GOV'T)LANGUAGE:
EnglishFILE SEGMENT:NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
FILE SEGMENT:Electronic; eCollection
FILE SEGMENT:PACTR
CLINICAL TRIAL NO.: PACTR201010000255244
ENTRY DATE:Entered STN: 27 Nov 2014
Last Updated on STN: 24 Dec 2014
ABSTRACT:BACKGROUND: Xpert MTB/RIF is approved for use in tuberculosis (TB) andrifampicin-resistance diagnosis. However, data are limited on the impact ofXpert under routine conditions in settings with high TB burden.
METHODS AND FINDINGS: A pragmatic prospective cluster-randomised trial of
Xpert for all individuals with presumptive (symptomatic) TB compared to theroutine diagnostic algorithm of sputum microscopy and limited use of culture
was conducted in a large TB/HIV primary care clinic. The primary outcome was
the proportion of bacteriologically confirmed TB cases not initiating TB. . .
diagnosis. Study limitations included incorrect intervention allocation for ahigh proportion of participants and that the study was conducted in a single
clinic.
CONCLUSIONS: These data suggest that in this routine primary care setting, useof Xpert to diagnose TB increased the number of individuals withbacteriologically confirmed TB who were treated by 3 mo and reduced time totreatment initiation, particularly among HIV-infected participants.
TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201010000255244.
Please see later in the article for the Editors' Summary.
GRANT FUNDING ORG.: United Kingdom Wellcome Trust
GRANT FUNDING NUM.: 085215
MEDLINE REFERENCE COUNT:
15
There are 15 cited references available in
MEDLINE for this document.
REFERENCE(S):CITED REFERENCES AVAILABLE IN MEDLINE FILE
(1) Anonymous; Lancet. 2014 Feb 1, V383(9915), P424-35. MEDLINE(2) Boehme, Catharina C; Lancet. 2011 Apr 30, V377(9776), P1495-505. MEDLINE(3) Boulle, Andrew; AIDS. 2010 Feb 20, V24(4), P563-72. MEDLINE(4) Boyles, T H; Int J Tuberc Lung Dis. 2014 Jul, V18(7), P876-8. MEDLINE(5) Cox, H; Int J Tuberc Lung Dis. 2014 Apr, V18(4), P441-8. MEDLINE(6) Getahun, Haileyesus; Lancet. 2007 Jun 16, V369(9578), P2042-9. MEDLINE(7) Helb, Danica; J Clin Microbiol. 2010 Jan, V48(1), P229-37. MEDLINE(8) Kwak, Nakwon; PLoS One. 2013, V8(10), Pe77456. MEDLINE(9) Langley, Ivor; Lancet Glob Health. 2014 Oct, V2(10), Pe581-91. MEDLINE(10) Lawn, Stephen D; Clin Infect Dis. 2006 Apr 1, V42(7), P1040-7. MEDLINE(11) Lawn, S D; Int J Tuberc Lung Dis. 2011 Mar, V15(3), P287-95. MEDLINE(12) Menzies, Nicolas A; PLoS Med. 2012, V9(11), Pe1001347. MEDLINE(13) Ridderhof, John C; Bull World Health Organ. 2007 May, V85(5), P354-9.
MEDLINE(14) Steingart, Karen R; Cochrane Database Syst Rev. 2013, V1, PCD009593.
MEDLINE(15) Theron, Grant; Lancet Infect Dis. 2014 Jun, V14(6), P527-32. MEDLINE
August 2023

16
MEDLINEDISPLAY IALL (OLDMEDLINE File Segment)
ACCESSION NUMBER:
1960033570
MEDLINE
DOCUMENT NUMBER:
PubMed ID: 13714019
TITLE:
Marie Curie and her contemporaries.
AUTHOR:de HEVESEY
SOURCE:
Journal of nuclear medicine : official publication, Societyof Nuclear Medicine, (1961 Jul) Vol. 2, pp. 169-82.
Journal code: 0217410. ISSN: 0161-5505. L-ISSN: 0161-5505.
DOCUMENT TYPE:
Biography
Journal; Article; (JOURNAL ARTICLE)LANGUAGE:
EnglishFILE SEGMENT:OLDMEDLINE; NONMEDLINEFILE SEGMENT:Print
ENTRY MONTH:
199811ENTRY DATE:Entered STN: 16 Jul 1999
Last Updated on STN: 16 Jul 1999
Entered Medline: 1 Nov 1998
SUPPLEMENTARY TERM: famous persons; radium
CONTROLLED TERM:*Famous Persons*History*Radium
NAMED PERSON:CURIE M
CAS REGISTRY NO.:
7440-14-4 (Radium)
UNIQ INGREDIENT ID: W90AYD6R3Q
OS.CITING REF COUNT: 1
There are 1 MEDLINE records that cite this record
DATE LAST CITED:
Date last citing reference entered STN: 16 Jul 1999
OS.CITING.REFS:MEDLINE 1964097687
DISPLAY IALL (IN-PROCESS Record)
ACCESSION NUMBER:
2015442702
MEDLINE (IN-PROCESS)
Full-text
DOCUMENT NUMBER:
PubMed ID: 25564676
TITLE:
2014: signaling breakthroughs of the year.
AUTHORS IN PUB ORD: Berndt Jason D; Wong Wei
AUTHOR:
Berndt Jason D
CORPORATE SOURCE:
Associate Editor of Science Signaling, American Association
for the Advancement of Science, 1200 New York Avenue, N.W.,
Washington, DC 20005, USA. jberndt@aaas.org; wwong@aaas.org
AUTHOR:
Wong Wei
CORPORATE SOURCE:
Senior Editor of Science Signaling, American Association
for the Advancement of Science, 1200 New York Avenue, N.W.,
Washington, DC 20005, USA. jberndt@aaas.org; wwong@aaas.org
SOURCE:
Science signaling, (2015) Vol. 8, No. 358, pp. eg1.
Electronic Publication Date: 6 Jan 2015
Journal code: 101465400. E-ISSN: 1937-9145.
DIGITAL OBJECT ID: http://dx.doi.org/10.1126/scisignal.aaa4696
PUB. COUNTRY:
United States
DOCUMENT TYPE:
Editorial
LANGUAGE:
EnglishFILE SEGMENT:NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED;
Priority Journals
FILE SEGMENT:Electronic
ENTRY DATE:Entered STN: 8 Jan 2015
Last Updated on STN: 8 Jan 2015
ABSTRACT:The 2014 breakthroughs fell into four main areas: innate immunity, host-microbe
interactions, cell death signaling, and methodological advances in the study of. . .
2014 saw the use of new techniques to study cell signaling and identify drug
targets, such as the in vivo use of RNA interference to study signaling in T
cells and new computational methods to study large datasets of different datatypes.
Copyright  2015, American Association for the Advancement of Science.

August 2023

17
MEDLINEDISPLAY BIB
AN2015434417
MEDLINE (IN-PROCESS)
Full-text
DN
PubMed ID: 25530753
TI
Incident duration modeling using flexible parametric hazard-based models.
AU
Li Ruimin; Shang Pan
AUID ORCID: http://orcid.org/0000-0002-3405-1143;
http://orcid.org/0000-0003-1715-456X
CS
Institute of Transportation Engineering, Department of Civil Engineering,
Tsinghua University, Heshanheng Building, Tsinghua, Beijing 100084, China.
SO
Computational intelligence and neuroscience, (2014) Vol. 2014, pp. 723427.
Electronic Publication Date: 4 Nov 2014
Journal code: 101279357. E-ISSN: 1687-5273.
Report No.: NLM-PMC4235144.
DOI http://dx.doi.org/10.1155/2014/723427
CY
United States
DT
Journal; Article; (JOURNAL ARTICLE)(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
EnglishFSNONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
FS
Print; Electronic
ED
Entered STN: 6 Jan 2015
Last Updated on STN: 8 Jan 2015
REM.CNT 10 There are 10 cited references available in MEDLINE for thisdocument.
DISPLAY TRIAL
TI
Just what the doctor ordered: the role of unconventional therapy in thetreatment of cancer in minors.
ST
In re Hofbauer; Professional Patient Relationship
CT*Adolescence*Amygdalin*Civil Rights
Decision Making
Government Regulation
Humans*Judicial Role
*Jurisprudence
Malpractice
Mentally Disabled Persons*Minors*Neoplasms. . .
PrivacySocial Control, Formal
Supreme Court Decisions
Terminally Ill*Third-Party Consent*Treatment Refusal
RN
29883-15-6 (Amygdalin)CN
0 (Pharmaceutical Preparations)
EXPAND in /CN Thesaurus=> E 9-XYLOSYLADENINE+ALL/CN
E1
E2
E3

16
0
0

E4
E5
E6
E7
E8
E9

0
0
0
0
0

--> 9-xylosyladenine/CN
RN
4185-03-9/CN
RR
28361-05-9/CN(((9alpha)-(L))-isomer)UF
9 beta-D-xylofuranosyladenine/CNUF
9 beta-D-xylosyladenine/CNUF
9-xylosyladenine, ((9alpha)-(L))-isomer/CN
UF
9H-purin-6-amine, 9-xylofuranosyl-/CN
UF
xyloA/CNUF
xylosyladenosine/CN
HM
Adenosine/*analogs & derivatives
NOTE RN given refers to cpd with unspecified isomeric
August 2023

18
MEDLINE*********

END

designation; structure in first source
PNTE XYLOSE/analogs (78-80)*********=> E 6-CHRYSENAMINE+XUSE/CN
E1
25--> 6-chrysenamine/CN
E20UF6-aminochrysene/CN
E30UF
6-chrysenylamine/CN
E40UF
6-chrysylamine/CN
E50UF
CP 1001/CN
E6
0UF
chrysenex/CN********* END *********EXPAND in /MN Thesaurus=> E D2.113.250.+ALL/MN
E1
BT3
D Chemicals and Drugs/MN
E2
BT2
Organic Chemicals/MN
E3
BT1
Anhydrides/MN
E4
BT4
D Chemicals and Drugs/MN
E5
BT3
Heterocyclic Compounds/MN
E6
BT2
Heterocyclic Compounds, 1-Ring/MN
E7
BT1
Furans/MN
E8-->
D2.113.250./MN
E9MH
Citraconic Anhydrides/MN
DC
an INDEX MEDICUS major descriptor
NOTE Methylmaleic anhydrides.
AQ
AD AE AG AI AN BL CF CH CL CS CT DU EC HI IM IP ME
PD PK PO RE SD ST TO TUURPNTE Anhydrides (1969-1974)
PNTE Maleates (1972-1974)
HNTE 91(79); was see under FURANS 1979-90; was
CITRACONIC ANHYDRIDE see under FURANS 1977-78 &see under MALEATES 1975-76
ONTE use CITRACONIC ANHYDRIDES to search CITRACONICANHYDRIDE 1975-78
MHTH NLM (1975)
E10
UF
Anhydrides, Citraconic/MN
E11
UF
Anhydrides, Methylmaleic/MN
E12
UF
Methylmaleic Anhydrides/MN********* END *********EXPAND in /CT Thesaurus=> E PLATELET AGGREGATION INHIBITORS+ALL/CT
E1
0
BT5
D Chemicals and Drugs/CT
E2
0
BT4
Chemical Actions and Uses/CT
E3
0BT3Pharmacologic Actions/CT
E4
16
BT2
Therapeutic Uses/CT
E5
281
BT1
Hematologic Agents/CT
E6
25622
-->
Platelet Aggregation Inhibitors/CT
E7
25622
MN
D27.505.954.502.780./CT
DC
an INDEX MEDICUS major descriptor
NOTE Drugs or agents which antagonize or impair any
mechanism leading to blood platelet aggregation,
whether during the phases of activation and shapechange or following the dense-granule release
reaction and stimulation of theprostaglandin-thromboxane system.
INDX DF: PLATELET INHIBAQAD AE AG AN BL CF CH CL CS CT DU EC HI IM IP ME
PD PK PO RE SD ST TO TU URPNTE Blood Platelets (1966-1987)
PNTE Platelet Adhesiveness (1972-1987)
PNTE Platelet Aggregation (1976-1987)
HNTE 88
MHTH NLM (1988)
E8
0UF
Agents, Antiplatelet/CT
August 2023

19
MEDLINE
E9
0
UF
E10
0
UF
E11
0
UF
E12
0
UF
E13
0
UF
E14
0
UF
E15
0
UF
E16
0
UF
E17
0
UF
E18
0
UF
E19
0
UF
E20
0
UF
E21
0
UF
E22
0
UF
E23
0
UF
E24
0
UF
E25
0
UF
E26
6490
NT1
E27
37205
NT1
E28
7292
NT1
E29
697
NT1
E30
11890
NT1
E31
1779
NT1
E32
2815
NT1
E33
1147
NT1
E34
3647
NT1
E35
918
NT1
E36
874
NT1
E37
1233
NT2
E38
918
NT2
E39
7156
NT1
E40
267
NT1
********** END **********

Aggregation Inhibitors, Platelet/CT
Antagonists, Blood Platelet/CT
Antagonists, Platelet/CT
Antiaggregants, Blood Platelet/CT
Antiaggregants, Platelet/CT
Antiplatelet Agents/CT
Antiplatelet Drugs/CT
Blood Platelet Aggregation Inhibitors/CT
Blood Platelet Antagonists/CT
Blood Platelet Antiaggregants/CT
Drugs, Antiplatelet/CT
Inhibitors, Platelet/CT
Inhibitors, Platelet Aggregation/CT
PLATELET AGGREGATION INHIB/CT
Platelet Antagonists/CT
Platelet Antiaggregants/CT
Platelet Inhibitors/CT
Alprostadil/CT
Aspirin/CT
Dipyridamole/CT
Disintegrins/CT
Epoprostenol/CT
Iloprost/CT
Ketanserin/CT
Milrinone/CT
Pentoxifylline/CT
S-Nitrosoglutathione/CT
S-Nitrosothiols/CT
S-Nitroso-N-Acetylpenicillamine/CT
S-Nitrosoglutathione/CT
Ticlopidine/CT
Trapidil/CT

DISPLAY BIB for EPUB AHEAD OF PRINT (NOTE: To manage the content of EPUB AHEAD OF PRINT records inyour answer set use: EPUB AHEAD OF PRINT/FS)
AN
2015441417
MEDLINE (EPUB AHEAD OF PRINT)
Full-text
DN
PubMed ID: 25565369
TI
Resistant Hypertension and Renal Denervation Where to Now?.
AU
Shaw James A
CS
Dept of Cardiology, Alfred Hospital, Baker IDI Heart and Diabetes
Institute.
AU
Warren JosephineSO
Cardiovascular therapeutics, (2015 Jan 7). Electronic Publication Date:
7 Jan 2015
Journal code: 101319630. E-ISSN: 1755-5922. L-ISSN: 1755-5914.
DOI http://dx.doi.org/10.1111/1755-5922.12103
DT
Journal; Article; (JOURNAL ARTICLE)LAEnglishFS
EPUB AHEAD OF PRINT; NONMEDLINE; NONINDEXEDFS
Print; Electronic
ED
Entered STN: 8 Jan 2015
Last Updated on STN: 8 Jan 2015

In North America

In Europe

In Japan

CAS Customer Center:
P.O. Box 3012
Columbus, Ohio 43210-0012
U.S.A.

CAS Customer Center EMEA
(represented by FIZ Karlsruhe)
P.O. Box 2465
76012 Karlsruhe
Germany

JAICI (Japan Association forInternational Chemical Information)
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021
Japan

Phone:
E-mail:Internet:

800-753-4227 (North America)
614-447-3731 (worldwide)
help@cas.org
www.cas.org

Phone:
E-mail:Internet:+49-7247-808-555
EMEAhelp@cas.org
www.stn-international.com

Phone:
E-mail:Internet:+81-3-5978-3601 (Technical Service)+81-3-5978-3621 (Customer Service)support@jaici.or.jp (Technical Service)customer@jaici.or.jp (Customer Service)www.jaici.or.jp

August 2023